Genetic abnormalities of patients with IGF-1Rabsent and IGF-1Rpresent MMCs and of patients with IL-6Rlow and IL-6Rhigh MMCs
| IGF-1R . | t(4;14)+ (n = 20), % . | t(4;14)− (n = 74), % . | IL-6R . | t(4;14)+ (n = 20), % . | t(4;14)− (n = 74), % . |
|---|---|---|---|---|---|
| IGF-1Rpresent | 70* | 26* | IL-6Rhigh | 85* | 53* |
| IGF-1Rabsent | 30* | 74* | IL-6Rlow | 15* | 47* |
| del13+ (n = 71), % | del13− (n = 59), % | del13+ (n = 71), % | del13− (n = 59), % | ||
| IGF-1Rpresent | 45* | 19* | IL-6Rhigh | 66* | 40* |
| IGF-1Rabsent | 55* | 81* | IL-6Rlow | 34* | 60* |
| del17+ (n = 24), % | del17− (n = 97), % | del17+ (n = 24), % | del17− (n = 97), % | ||
| IGF-1Rpresent | 58* | 27* | IL-6Rhigh | 46 | 58 |
| IGF-1Rabsent | 42* | 73* | IL-6Rlow | 54 | 42 |
| 1q21+ (n = 48), % | 1q21− (n = 66), % | 1q21+ (n = 48), % | 1q21− (n = 66), % | ||
| IGF-1Rpresent | 42* | 27* | IL-6Rhigh | 67* | 47* |
| IGF-1Rabsent | 58* | 73* | IL-6Rlow | 33* | 53* |
| t(11;14)+ (n = 15), % | t(11;14)− (n = 104), % | t(11;14)+ (n = 15), % | t(11;14)− (n = 104), % | ||
| IGF-1Rpresent | 33 | 33 | IL-6Rhigh | 40* | 57* |
| IGF-1Rabsent | 67 | 67 | IL-6Rlow | 60* | 43* |
| IGF-1R . | t(4;14)+ (n = 20), % . | t(4;14)− (n = 74), % . | IL-6R . | t(4;14)+ (n = 20), % . | t(4;14)− (n = 74), % . |
|---|---|---|---|---|---|
| IGF-1Rpresent | 70* | 26* | IL-6Rhigh | 85* | 53* |
| IGF-1Rabsent | 30* | 74* | IL-6Rlow | 15* | 47* |
| del13+ (n = 71), % | del13− (n = 59), % | del13+ (n = 71), % | del13− (n = 59), % | ||
| IGF-1Rpresent | 45* | 19* | IL-6Rhigh | 66* | 40* |
| IGF-1Rabsent | 55* | 81* | IL-6Rlow | 34* | 60* |
| del17+ (n = 24), % | del17− (n = 97), % | del17+ (n = 24), % | del17− (n = 97), % | ||
| IGF-1Rpresent | 58* | 27* | IL-6Rhigh | 46 | 58 |
| IGF-1Rabsent | 42* | 73* | IL-6Rlow | 54 | 42 |
| 1q21+ (n = 48), % | 1q21− (n = 66), % | 1q21+ (n = 48), % | 1q21− (n = 66), % | ||
| IGF-1Rpresent | 42* | 27* | IL-6Rhigh | 67* | 47* |
| IGF-1Rabsent | 58* | 73* | IL-6Rlow | 33* | 53* |
| t(11;14)+ (n = 15), % | t(11;14)− (n = 104), % | t(11;14)+ (n = 15), % | t(11;14)− (n = 104), % | ||
| IGF-1Rpresent | 33 | 33 | IL-6Rhigh | 40* | 57* |
| IGF-1Rabsent | 67 | 67 | IL-6Rlow | 60* | 43* |
Interphase FISH analysis was performed on CD138-purified plasma cells for 79 to 129 patients of the HM series. Patients were separated into 2 groups: patients with IGF-1Rabsent MMCs and patients with IGF-1Rpresent MMCs or patients with IL-6Rlow MMCs and IL-6Rhigh MMCs, as assayed with Affymetrix microarrays. Data are the percentages of patients within these 2 groups with the biologic parameters.
The percentages were different with a χ2 test (P ≤ .05).